Janssen vaccine increases risk of Guillain-Barre syndrome

The U.S. Food and Drug Administration (FDA) has warned against possible side effects from the Covid-19 "Janssen" vaccine.

The serum developed by Johnson & Johnson would significantly increase the risk of Guillain-Barre syndrome, a rare disease that affects the neurological system.

Data collected by U.S. health authorities indicate that 100 out of 12.5 million people who received the Janssen jab have developed the syndrome. Signs of the disease emerge within 42 days of vaccine administration.